Primary central nervous system lymphoma
Clinical trials for Primary central nervous system lymphoma explained in plain language.
Never miss a new study
Get alerted when new Primary central nervous system lymphoma trials appear
Sign up with your email to follow new studies for Primary central nervous system lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can an immune booster outsmart brain lymphoma?
Disease control Not yet recruitingThis trial is testing whether adding an immunotherapy drug called penpulimab to a standard chemotherapy regimen can help people with primary central nervous system lymphoma, a rare type of brain cancer. Participants, who have not yet received treatment, are randomly assigned to r…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Sponsor: WEI XU • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Experimental CAR T-Cell therapy takes on recurrent brain cancer
Disease control Not yet recruitingThis early-stage trial is testing a new treatment called CHT101 for adults with aggressive brain tumors that have returned or worsened despite standard care. CHT101 is a type of immune cell therapy (CAR T-cells) designed to recognize and attack tumor cells carrying a protein call…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase 1 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New model aims to prevent kidney failure in brain cancer therapy
Knowledge-focused Not yet recruitingThis study looks at 50 adults with primary central nervous system lymphoma who are receiving high-dose methotrexate, a key chemotherapy. The goal is to see if measuring the drug early in the blood can predict later kidney problems. By identifying at-risk patients sooner, doctors …
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC